Jubilant Ingrevia Announces Audited Financial Results for FY2026
Jubilant Ingrevia Limited today announced the audited financial results for the quarter and full financial year ended March 31, 2026. The company's Board of Directors formally approved the results, and the statutory auditors provided an unmodified opinion on both the consolidated and standalone financial statements.The company also provided key operational updates, including the recommendation of a final dividend and details regarding recent business acquisitions that enhance its value chain in human nutrition and pharmaceutical manufacturing.
Financial Performance Highlights
The audited results for the year ended March 31, 2026, show total revenue from operations of 438,807 and a total income of 442,860 (in Lakhs, based on the published units).Consolidated Annual Results (Year Ended March 31, 2026)
The consolidated statement showed robust performance in the year ending March 31, 2026. Total income stood at 442,860, leading to a net profit attributable to owners of the company of 27,791. Total comprehensive income reached 29,823.
For comparison, the previous year (2025) reported a total income of 421,543 and a net profit of 25,117.
| Metric | FY 2026 (Audited) | FY 2025 (Audited) |
|---|---|---|
| Total Revenue from Operations | 438,807 | 417,761 |
| Total Income | 442,860 | 421,543 |
| Net Profit (Owners of Company) | 27,791 | 25,117 |
| Total Comprehensive Income | 29,823 | 25,295 |
Standalone Annual Results (Year Ended March 31, 2026)
On the standalone basis, the company reported total revenue from operations of 413,849 for the year ending March 31, 2026. The net profit for the year was 26,797, with total comprehensive income amounting to 26,812.
| Metric | FY 2026 (Audited) | FY 2025 (Audited) |
|---|---|---|
| Total Revenue from Operations | 413,849 | 394,123 |
| Total Income | 423,818 | 402,224 |
| Net Profit | 26,797 | 26,342 |
Strategic and Operational Updates
The Board of Directors held its meeting on May 26, 2026. During the meeting, the board recommended a final dividend of ₹2.5 per equity share (₹1 each) for the year ended March 31, 2026, subject to approval at the Annual General Meeting. This increases the total dividend for the year to ₹5 per equity share.In terms of strategic growth, Jubilant Ingrevia completed a significant business acquisition, securing a 100% stake in Remidex Pharma Private Limited with effect from March 30, 2026. This acquisition, which was finalized via a Share Purchase Agreement for a consideration of ₹1,628 lakhs, enhances the company's ability to progress in the value chain toward premixes in human nutrition and pharmaceutical manufacturing.
Financial Ratios Overview
The company provided an overview of several key ratios, indicating stable financial health and growth in market metrics.Consolidated Financial Ratios (March 31, 2026 vs March 31, 2025)
| Ratio | 31 March 2026 | 31 March 2025 |
|---|---|---|
| Debt service coverage ratio (in times) | 4.68 | 6.96 |
| Interest service coverage ratio (in times) | 14.55 | 10.01 |
| Bad debts to account receivable ratio (%) | 0.03% | 0.03% |
| Debtors turnover (in times) | 1.60 | 0.15 |
| Operating margin (%) | 9.69% | 8.65% |
| Net profit margin (%) | 7.28% | 5.96% |
| Current ratio (in times) | 1.29 | 1.32 |
| Debt equity ratio (in times) | 0.19 | 0.22 |
Segment Revenue Performance
Consolidated revenue remained strong across key segments. Speciality Chemicals recorded 193,650, Nutrition & Health Solutions generated 78,970, and Chemical Intermediates contributed 166,187, bringing the total revenue from operations to 438,807 for the year.
Additional Notes
The annual results include an additional employee benefit expense of ₹1304 lakhs presented under "Exceptional Items." This expense was recorded due to the mandatory changes in employee benefit calculation resulting from the enactment of the 'New Labour Codes,' effective November 21, 2025. The company noted that it continues to monitor developments concerning these Labour Codes.The financial results are based on comprehensive reporting standards, providing both consolidated and standalone statements of results, assets, and liabilities.
JUBLINGREA Stock Price Movement
Shares of Jubilant Ingrevia Limited today slipped by 1.95% to settle at ₹717.5. The stock saw a total volume of 184,716 shares traded today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: